Margaret Johnson, MD

Royal Free London NHS Foundation Trust, United Kingdom

Disclosure(s): Merck & Co., Inc.: Grant/Research Support

Poster(s):

• (P-369) Safety and Efficacy of Doravirine/Islatravir (DOR/ISL) 100/0.25 mg Once Daily (QD) after ISL Dose Reduction from 0.75 mg: Week 48 Results from an Open-Label Phase 3 Study
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET